Aims/hypothesis Islet cell death is a key initiating and perpetuating event in type 1 diabetes and involves both immune-mediated and endogenous mechanisms. The epithelial pantetheinase vanin-1 is proinflammatory and cytoprotective via cysteamine release in some tissues. We investigated the impact of a vanin-1 deficiency on islet death and type 1 diabetes incidence.
Introduction
Type 1 diabetes is an autoimmune disease leading to a T cell-mediated destruction of insulin-producing islet cells. Loss of tolerance towards islet cell antigens plays a decisive role in the appearance of the disease [1] [2] [3] [4] . However, to date still poorly identified intrinsic and environmental factors such as diet or infections can increase immunemediated diabetogenic inflammation and islet cell death [5, 6] . In the NOD mouse model, disease progression proceeds through two sequential checkpoints [7] . Checkpoint 1 refers to the early accumulation of lymphocytes around islets after 3 weeks of age; this peri-insulitis progresses towards overt insulitis. Transition to insulitis might involve the abrupt release of pancreatic autoantigens upon stress or major metabolic changes provoked by weaning. Checkpoint 2 comprises progression to islet cell destruction and diabetes. During the Th1-driven aggressive phase of the disease, islet cell death is provoked by a combined lymphocyte-dependent Fas-, perforin-or cytokine-mediated cytotoxicity [8, 9] . Proinflammatory cytokines such as IL-1, TNF and IFNγ synergise to induce islet beta cell death [10, 11] or to prime for Fas-mediated lysis [12, 13] , but taken independently, each molecule is dispensable for diabetes progression [8, 14, 15] . These cytokines reflect the presence of activated myeloid cells, which contribute to lymphocyte retention [16, 17] and generate oxidative stress in islets thus aggravating diabetes. Several investigations suggest that islet cells are particularly sensitive to oxidative stress [18] . Furthermore administration or transgenic overexpression of antioxidants can prevent diabetes onset [19] [20] [21] . Thus, regulators of inflammation and oxidative stress can influence diabetes by acting at the level of islet or immune cells. However, the relative contribution of cytoprotective versus destructive factors is unclear.
Vanin-1 is a pantetheinase expressed at the extracellular membrane of several epithelial tissues in mouse and man. Vanin-1 acts by locally modifying epithelial cell response to stress via pantetheinase-mediated cysteamine production [22] . Cysteamine and its oxidised form cystamine is a small thiol-containing compound suspected to modulate intracellular enzymatic activities involved in stress response and/or inflammation. Vanin-1-deficient (V1 −/− ) mice have undetectable levels of tissue cysteamine and display an enhanced resistance to systemic oxidative stress and intestinal inflammation [23] . In gut, the licensing role of vanin-1 in inflammation is in part explained by the cysteaminemediated inhibition of glutathione synthesis [24] and peroxisome proliferator-activated receptor (PPAR)γ's antiinflammatory function [25] . Under acute stress, vanin-1 behaves as an epithelial sensor that modulates the threshold of tissue response to stress and immune reactivity. However, cysteamine function may not be limited to the control of inflammation. In various models of neurodegenerative diseases [26] [27] [28] , cystamine attenuates the severity of lesions by an as yet unknown mechanism. Since cysteamine is ubiquitously expressed in epithelial tissues, it might be either proinflammatory or cytoprotective in diabetes. We directly tested this hypothesis in drug-induced and autoimmune forms of the disease. Our results show that the absence of vanin-1 leads to greater diabetes incidence in all experimental models. This aggravation is explained by the loss of cysteamine-mediated islet cytoprotection rather than via an impact on inflammation. Thus cysteamine plays a major role in islet cell homeostasis during diabetes progression. Analysis of infiltrating haemopoietic cells Pancreases removed from 6-to 12-week-old female mice were cut in pieces and digested with collagenase IV (Serlabo, Entraigues sur la Sorgue, France) at 0.2 mg/ml in RPMI, 20 mmol/l HEPES, 2% FCS (vol./vol.) for 30 min. Infiltrating cells were recovered as single cell suspensions after filtration on cell strainer (70 μm nylon; BD Biosciences) and Ficoll purification. Cells were directly labelled with combinations of allophycocyanin (APC)-coupled anti-CD4, peridininchlorophyll-protein complex (Per-CP)-coupled anti-CD8, Per-CP-coupled anti-CD25 or anti-CD3, biotinylated anti-B220 or anti-CD11c, and FITC-coupled anti-CD11b mAbs (BD Biosciences).
Methods

Mice and reagents
Islet isolation and culture Langerhans islets were isolated from pancreas by digestion with collagenase P (1 mg/ml) (Roche Molecular Biochemicals) at 37°C for 20 min and further separated using a density gradient (Histopaque-1077; Sigma). Islets were handpicked and incubated in rich medium supplemented with 10% FCS (vol./vol.) and antibiotics. Islets (100-200) were cultured overnight in RPMI medium containing 10% bovine serum albumin (vol./vol.), 5% penicillin-streptomycin (vol./vol.) before transplantation and in vitro studies. Islets were dispersed into single cell suspensions with 0.2% trypsin (wt/vol.; Gibco, Invitrogen), 10 mmol/l EDTA in Hanks' buffered salt solution. Islets were used directly after trypsin dissociation to extract RNA. For cytokine stimulation, islets were incubated overnight in CMRL (Connaught Medical Research Laboratories)-1066 medium (Invitrogen) with 10% FCS (vol./vol.) and antibiotics and exposed for 4 to 5 days to IL-1β (10 ng/ml; Sigma) and IFN-γ (100 ng/ ml; Abcys biologie, Paris, France). For STZ-induced apoptosis [33] , islets were incubated for 20 h in medium containing 0.5 mmol/l STZ (Sigma) dissolved in 0.1 mmol/l citrate buffer (pH 4.5). Cystamine was added to islet cultures at a final concentration of 100 μmol/l.
Apoptosis assay Islets were cultured for 5 days with cytokines, then dispersed into a single-cell suspension with trypsin, followed by recovery in complete medium at 37°C for 30 min. Cell suspensions were incubated overnight in the dark in a 50 μg/ml propidium iodide, 0.1% sodium citrate (wt/vol.) and 0.1% Triton X-100 (vol./vol.) solution at 4°C. Nuclear fragmentation was analysed on a flow cytometer [34] . The level of induced apoptosis was determined by the formula: 100×(% apoptotic cells with cytokine or STZ−% background apoptotic cells)/(100−% background apoptotic cells).
Cytokine antibody array Mouse cytokine antibody arrays were incubated overnight at 4°C with 500 μg of total CY-treated pancreatic lysates according to the manufacturer's instructions (RayBiotech, Norcross, GA, USA) and quantified using a chemiluminescence imaging system (Intelligent Dark Box II; FUJIFILM, Saint-Quentin en Yvelines, France). Relative cytokine expression levels were determined using the Multi Gauge V2.3 software (FUJIFILM). Internal controls included in the array were used to normalise the results from different membranes. Statistical analysis Kaplan-Meier graphs showing diabetes incidence were analysed using the log rank test. For in vitro assays, Student's t, ANOVA or Kruskal-Wallis tests were used as indicated.
Results
Vanin-1 regulates islet sensitivity to cell death induction Islet cell death is a main determinant of diabetes progression and can be the consequence of various stresses [9] . We first checked whether vanin-1 deficiency would affect glucose metabolism. Both basal glucose levels, Glut2 (now known as Slc2a2) mRNA expression and intravenous glucose tolerance tests were assayed and found to be normal in V1 −/− mice (data not shown). Islet fragility was then explored by injecting in vivo STZ, a known inducer of islet cell death. Multi low dose STZ administration to V1 −/− BALB/c mice provoked a twofold increase in diabetes incidence compared with control mice (log rank test: p< 0.05) and was accompanied by a higher level of haemopoietic cell infiltration (Fig. 1a-c) . This result was confirmed in vitro by culturing BALB/c islets in the presence of STZ. As shown in Fig. 1d , V1 −/− islets were twofold more susceptible to cell death induction than control islets and this effect was reversed by cystamine (unidirectional Kruskal-Wallis test: p<0.01). Caspase-3 is a main actor of STZ-induced cell death [33] . Thus we analysed by immunofluorescence the expression of active caspase-3 in These results document a statistically significant in vitro and in vivo cytoprotective effect on islets.
Increased insulitis and diabetes in V1 −/− NOD mice We then tested whether this cytoprotective effect could modulate autoimmune diabetes. The vanin-1 deletion was introduced on the NOD background and vanin-1 expression was checked by quantitative RT-PCR on whole NOD pancreas and isolated islets. A similar level of expression was found in both exocrine and endocrine tissues in 3-and 8-week-old NOD mice (Fig. 2a) . Then, diabetes incidence was monitored by measuring glycosuria in V1 −/− and control NOD mice (Fig. 2b,c) . In our NOD mouse colony, spontaneous incidence was around 50% in 30-week-old female mice, whereas male NOD mice did not develop diabetes. In contrast, 75% V1 −/− female mice became diabetic within 25
weeks (log rank test: χ 2 =18.24; p<0.0001). Some 30% male mice also developed diabetes within 40 weeks (log rank test: χ 2 =4.26; p<0.05). We then compared the degree of insulitis at 6, 8 and 12 weeks of age (Fig. 2d) . A moderate insulitis is detectable in 6-week-old NOD mice and is associated with a destruction of 30% islets in 12-week-old mice in agreement with diabetes incidence. The degree of islet infiltration was more severe at all time points in V1 −/− mice and around 50%
islets were destroyed at 8 weeks. Since islet survival depends upon equilibrium between destruction and regeneration, we quantified the amount of cycling islet cells following BrdU administration and compared it to the degree of infiltration. As shown in Fig. 2e -g, the percentage of BrdU-positive CD45−, insulin-producing epithelial cells was twice as high in V1 −/− animals in a context of higher infiltration (p<0.01),
suggesting that islet proliferation was not globally impaired in the mutant mice. Vanin-1-dependent protection against diabetes is mediated by host tissue To check the contribution of host epithelial vanin-1, we used a transfer model in which total splenocytes from diabetic mice were injected into 6-week-old irradiated male NOD recipients. In this experimental setup, diabetes appears between 5 and 10 weeks after transfer in 50% NOD recipient mice (Fig. 3) . The same population of NOD-derived diabetogenic splenocytes provokes a more rapid (2-3 vs 4-5 weeks) and more penetrative (90% vs 50%) diabetes in V1 −/− NOD recipient mice (log rank test: χ 2 =7.32; p=0.0068). Thus V1 −/− islets are more permissive to infiltration and/or effector cell activation. This could be explained by a differential response of host tissues to immune stress or to the impact of host tissue on the triggering of immune functions.
Vanin-1 deficiency is associated with enhanced Th1 responses The more aggressive insulitis observed in the spontaneous disease might be due to a cystamine-mediated skewing in immunocyte recruitment and/or activation. We performed a flow cytometric analysis of infiltrating cells in pancreas ( (Fig. 4a) , but did not document significant variations between control and vanin-1-deficient islets. A complementary analysis was performed using a chemokine/cytokine array in a CYinduced diabetes model, which allows samples to be analysed at a precise timing following CY-mediated triggering of diabetes. Results obtained from whole pancreatic extracts (Fig. 4b) revealed a modest decrease in levels of MIP1γ, MIP2, MIP3 and regulated upon activation, normal T cells expressed and secreted (RANTES) in V1 −/− mice, which might explain the reduction in macrophage infiltration. Concerning cytokines, quantitative RT-PCR analysis on isolated islets showed a significant increase (p<0.05) in the expression of iNOS mainly (Fig. 4a ) documenting a skewing towards M1 cell polarisation. Cytokine secretion by T lymphocytes was also checked by direct activation of enriched CD45+ cells from pancreases. Whereas IFNγ secretion and FasL expression could be detected on CD3/ CD28-activated CD4+and CD8+T lymphocytes isolated from pancreatic infiltrates, no statistically significant difference was observed between control and V1 −/− NOD mice (data not shown). Since Th1-dependent proinflammatory cytokines provoke islet death, we cultured V1 −/− or control NOD islets in the presence of IL-1β and IFNγ. As shown in Fig. 4c , both basal and cytokine-induced islet death was comparable, irrespective of the presence of the vanin-1 molecule. Thus, cystamine does not modulate cytokine-induced cell death pathways under these experimental conditions.
Vanin-1 deficiency is not associated with regulatory T cell deficiency Progression towards the aggressive phase of diabetes requires an imbalance between effector cells and regulatory T cells (Tregs) [1, 36] . Thus the increased CD4 Fig. 3 Impact of host epithelial vanin-1 on diabetes. Diabetogenic lymphocytes ( 10 7 ) from diabetic NOD mice were injected i.v. 24 h after irradiation (6 Gy) into 6-week-old male NOD (white symbols; n=44) or V1 −/− NOD (black symbols; n=60) irradiated recipients. Results represent the average of seven independent transfers ( ¶ p=0.0068) Values are the percentage of positive cells for the different leucocyte markers Flow cytometric analysis of infiltrating leucocytes was performed by pooling three to four control or V1 −/− NOD mice per experimental point and analysing three to four independent experiments. SD was calculated between experimental points for each condition cell infiltration in V1 −/− NOD mice could be due to a reduced control by Tregs. To test this possibility, we developed a model of CY-induced diabetes in male NOD mice. CY acts by depleting proliferating lymphocytes including Tregs, leading to abrupt diabetes onset [37] . After two CY injections, 30 to 40% of 8-week-old male NOD mice developed diabetes within 20 days (Fig. 5a ). In contrast, 40 and 95% of V1 −/− NOD mice developed diabetes after the first and second injection, respectively (log rank test: χ 2 =10.72; p=0.001). This result was correlated with an aggravated insulitis as observed in the natural disease (data not shown). This model system recapitulates the aggravating effect of vanin-1 deficiency. Both NOD and V1 −/− NOD mice display the same proportion of Tregs (between 0.5% and 2%). We then comparatively tested their relative potency by injecting sorted CD4+CD25+Tregs into CY-treated V1 −/− NOD mice. As shown in Fig. 5b , the intravenous administration of NOD or even more V1 −/− NOD Tregs significantly reduced diabetes onset (log rank test: χ 2 =15.91; p= 0.0003). Thus the aggravated diabetic phenotype cannot be explained by a deficiency in Tregs in V1 −/− NOD mice.
Cystamine prevents CY-induced diabetes and limits diabetes incidence in V1 −/− mice These results suggest that cystamine administration might provide a novel strategy to limit islet cell death in ongoing diabetes. We thus injected cystamine in short-term CY-induced and spontaneous diabetes models. As shown in Fig. 6a , this treatment, given 2 days before and for the first 8 days following CY injection, provoked a drastic reduction in diabetes onset (log rank test: χ 2 =15.67; p<0.0001). However, once cystamine administration was interrupted and after a second CY injection, diabetes bounced back. We then treated V1 −/− or control NOD mice during the pre-diabetic period (for 20 weeks). As shown in Fig. 6b , cystamine administration reduced diabetes incidence in V1 −/− NOD mice, which slowly reappeared progressively after therapy ceased (data not shown). However, in this assay, the repetitive, long- term and stressful intra-peritoneal injections of PBS reduced the spontaneous incidence of diabetes in the colony from 75% to 52% thereby limiting the statistical significance of cystamine effect on the treated cohort (p=0.08).
Discussion
Current understanding of the physiopathology of diabetes sees islet cell death as a key initiating and perpetuating event. The mechanisms involve developmental alterations, environmental insults, inflammatory and autoimmune processes [9] . Whereas immune and inflammatory effectors play a major role once the disease has started, the early death-inducing events might involve metabolic stress after weaning, alterations in prostaglandins homeostasis, which are responsible for endothelial dysfunction, or sensitivity of islet cells to oxidative stress [18, 38] . Islet cell destruction provokes the release of pancreatic autoantigens and, in a susceptible background, autoimmunity. Mechanistically, the early insult and delayed immune-mediated damage provoke caspase-dependent apoptosis and cytokine-dependent necrosis of islet cells [11, 33] . An appropriate control of the disease should target early and late phases by inhibition of immune effectors [39] complemented by islet cytoprotection.
Vanin-1/pantetheinase provides tissue cysteamine, a proinflammatory molecule in gut acute stress [24, 25] . Consequently, vanin-1 deficiency might limit diabetes incidence in NOD mice. Alternatively, cysteamine has been shown to exert putative cytoprotective functions in neurodegenerative diseases. In this latter situation, its deficiency would further aggravate diabetes. Our results clearly indicated that in both drug-induced and autoimmune diabetes, disease incidence increased in the absence of cysteamine. In the NOD model, the aggravation was characterised by a more aggressive insulitis with islets enriched in CD4 Th1 lymphocytes. This enhanced Th1 response is not explained by a regulatory T cell deficiency. Efficient Th1 responses usually require powerful inflammatory signals, which were previously shown to be enhanced by vanin-1/cysteamine in gut infection or colitis models. In these models, inflammation is triggered by danger signals emanating from commensal or exogenous microbes. To evaluate islet susceptibility to vanin-1-mediated inflammation, we grafted them under the kidney capsule, a process known to generate proinflammatory danger signals [40] . These experiments indicated that irrespective of the vanin genotype of the grafted islets, inflammation was mainly determined by the genotype of the recipient kidney (data not shown). Indeed, in this experimental set up, inflammation was driven by the high levels of vanin-1 expression in kidney, which dominated the cytoprotective potential conferred by the low level of vanin-1 expression in islets. Thus cysteamine impact on disease may directly depend upon local tissue concentrations. In spontaneous diabetes, low-grade inflammation proceeds progressively in the absence of acute trauma; in this context, vanin-1 behaves as a cytoprotective rather than a proinflammatory molecule. The mechanisms of control of inflammation versus survival by cysteamine are poorly characterised. We previously demonstrated that cysteamine amplifies stress responses by altering redox metabolism and PPARγ activation, both involved in regulation of the nuclear factor kappa B (NF-κB) pathway [41, 42] . An islet cell-specific inhibition of this pathway abrogates cytokineor STZ-induced cell death [43] . In the absence of vanin-1, the diabetogenic effect of these treatments is unaltered or enhanced. Thus, under these experimental conditions, cysteamine rather behaves as a negative regulator of cell death. The question of whether this occurs through regulation of NF-κB activation remains to be answered, but this regulation is probably distinct from that involved in the enhancement of inflammation downstream of pattern recognition receptor-signalling in acute inflammatory models.
We currently favour the hypothesis that a basal cysteamine concentration limits stress-induced tissue destruction. Whereas it can protect from induced diabetes after a single CY injection, it cannot fully protect from STZ-induced or spontaneous autoimmune diabetes. In the latter model, Fig. 6 Protective role of cystamine administration on diabetes incidence in V1 −/− NOD mice. a CY-induced diabetes. Cystamine (CA) was given 2 days before and 8 days after a first CY injection in NOD (n=5) or V1 −/− NOD mice (n=17). Cystamine administration was interrupted after 10 days, followed by a second CY injection. Diabetes incidence was then followed for up to 50 days. Results represent average of two independent experiments. The log rank test was performed on these cohorts ( † p<0.0001). b Spontaneous diabetes: cystamine was administrated four times per week during 20 weeks and the number of diabetic mice is shown at 10, 15, 20 and 25 weeks in these cohorts (p=0.08) aggravation of diabetes is strictly dependent upon host tissues and not linked to major alterations of immune responses. In vitro islet cultures mirror tissue resistance in short-term experiments. This suggests that islets are intrinsically modified in their ability to handle stress and that vanin-1/cysteamine regulate islet cell homeostasis. For a definitive molecular explanation, a better understanding of cysteamine action on intracellular pathways will be required. Several non-mutually exclusive possibilities can be envisaged. Few putative enzymatic cysteamine targets have been characterised: they include transglutaminases [44] , caspase 3 and protein kinase C (PKC)ɛ. STZ-induced cell death is dependent upon caspase 3 activation [33] . Interestingly, cystamine can partially inhibit caspase 3 in vitro [45] and this mechanism might contribute to its protective effect in Huntington's disease [26, 27] . Since it is not known whether cystamine can regulate the activity of other caspases, more extensive studies are required to establish this. Cysteamine also inhibits PKCɛ [46] , which regulates signal transducer and activator of transcription-1-dependent activation [47] , a key effector arm in diabetes progression [48] . Irrespective of the mechanism involved, our results document a novel biological function of cysteamine through its ability to regulate islet beta cell survival, a mechanism which might also be involved in neuroprotection [28] . More generally, external events capable of altering cysteamine levels in islets could modulate diabetes progression, thus offering an alternative way of controlling the early islet cell destruction occurring in type 1 diabetes.
